IDH1 and grade III glioma: The randomized, open-label, phase 3 CATNON trial offers evidence that temozolomide adjuvant but not concurrent to a radiotherapy is associated with a survival benefit in non 1p/19q co-deleted anaplastic glioma with IDH1/2 mutation, however, not effective in IDH1/2 wildtype tumors [12, 13].